Litt spennende nå… Har vi fått test av støttelinje og endelig bekreftelse av den rounding bottom som jeg har messet om siden februar? 
Er i hvert fall litt økende volum nå i det den drar seg overMA50:
Episurf Medical (Nasdaq: EPIS B) today announces the initiation of a prospective investigator-initiated European multicentre study with 5 years follow-up of 25 Episealer Talus patients. The study is initiated by Prof. Niek van Dijk from FIFA Medical Center of Excellence, Madrid, Spain and surgeries will be performed in a number of European countries. The patients in the study will be followed up over 5 years with the subjective outcome measures VAS pain score, Foot and Ankle Outcome Score (FAOS) and EQ-5D-5L which is an instrument used for evaluation of life quality. Interim results from 2 years follow-up are scheduled to be submitted for publication. The first clinic to enroll patients in the study is Arcademy Clinic at Sophiahemmet, Stockholm, Sweden, lead of MD, PhD Jouko Kivioja who was also the first Episealer Talus user in Scandinavia. Episealer Talus is Episurf Medicals CE marked joint implant intended for treatment of osteochondral ankle lesions.
I am pleased with this study design and it is important to gather clinical data for this promising technology, says Prof. Niek van Dijk.
Robust clinical evidence is very important for us at Episurf and we are happy that a user group lead by Prof. Niek van Dijk decided to take this initiative, says Pål Ryfors, CEO Episurf Medical.
4 Likes
Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from a Swedish multicentre clinical study with 5 years follow-up of Episealer Knee patients has been accepted for presentation at the upcoming ISAKOS 2021 Global Congress. The abstract, Good Subjective Outcome And Low Risk Of Revision Surgery With A Novel Customized Metal Implant For Focal Femoral Chondral Lesions At A Minimum Of Five Years Follow-Up, will be presented by Associate Professor Anders Stålman, Capio Artro Clinic, Stockholm, Sweden.
ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine) is an international organisation with the mission to advance the worldwide exchange and dissemination of education, research and patient care in arthroscopy, knee surgery and orthopaedic sports medicine. The ISAKOS 2021 Global Congress will be held online on November 27-28.
The abstract reports on the clinical outcome of the 10 first Swedish Episealer patients, that have undergone treatment with Episurf Medicals individualised knee implant Episealer for treatment of isolated chondral and osteochondral defects in the knee.
We have now come to a stage where we see mid- to long-term results being available for presentation and publication and we are pleased that this scientific abstract with clinical results from the very first Swedish Episealer patients has been accepted for presentation at this international congress, says Pål Ryfors, CEO Episurf Medical.
3 Likes
Hehe… hadde faktisk tenkt å spørre deg om ikke dette er et flagg etter din smak 
Det er jo ikke helt “ryddig”, streken jeg har tegnet for å få et flagg går jo gjennom masse wicks, men synes volumet og candles danner et pent flagg. Formasjonen skal ikke trekke ut så mye lengre nå før jeg mener den er ugyldig dog. Er vel grei i 2-3 dager til.
2 Likes
Dessverre gjorde ikke det flagget mye ut av seg og i dag bikket den også under MA50 og MA150.
Skal vi nå ned igjen mot 3,10 der også MA200 ligger for øyeblikket?? 
5 Likes
EPISURF
Episurfs ordförande Dennis Stripe gör ett mindre aktieköp (Finwire)
2021-08-25 15:26
Medicinteknikbolaget Episurf Medicals styrelseordförande Dennis Stripe har den 24 august köpt 18 000 B-aktier i bolaget. Aktierna köptes till kursen 3,28 kronor per aktie, en affär på 59 000 kronor. Affären gjordes på Nasdaq Stockholm. Det framgår av Finansinspektionens insynsregister.
Henrik Öhlin
henrik.ohlin@finwire.se, 0703-21 06 99
Nyhetsbyrån Finwire
4 Likes
Alle monner drar!
Volum og brudd over 3,58ish hadde gjort seg nå. Håper en godmelding kan gjøre susen, men uansett positivt at den ikke har falt gjennom støtten på 3,10 - 3,15:
5 Likes
Stanger i 3,58 i dag. Spennende 
2 Likes
Estland i gang med Talus protesen:
Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery with the ankle implant Episealer Talus in Estonia has been scheduled.
It is pleasing that more and more patients globally can be helped by the Episealer technology, with Estonia being the most recent addition on our global strategy, says Pål Ryfors, CEO Episurf Medical.
Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from follow-up of Episealer Knee implant patients will be presented by Priv.-Doz. Dr. med. Clemens Kösters at the 38[th] annual AGA Congress in Innsbruck, Austria, which will take place on September 9-11.
The abstract with the title Good clinical results after implantation of single vs. multiple patient-specific mini-implants in therapy-resistant focal femoral (osteo-) chondral lesions in middle-aged patients presents the clinical outcome for patients who received multiple Episealer implants compared with the results for patients who received one Episealer implant for treatment of focal chondral and osteochondral defects in the knee.
Our results astonishingly demonstrated that the clinical results of patients with 2 or 3 Episealer implants were just as good as those with 1 Episealer implant. Furthermore, both groups did not show any complications says Priv.-Doz. Dr. med. Clemens Kösters.
The use of 2-3 implants has become relatively frequent among some of the Episealer surgeons, but publications of clinical follow-up data are limited. We look forward to seeing the results from this independent group of authors presented at this important congress says Pål Ryfors, CEO Episurf Medical.
AGA-Society for Arthroscopy and Joint-Surgery is a German speaking scientific organisation and one of Europes largest professional organisations within arthroscopy and joint-surgery.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
3 Likes
Jepp, meldingspressa til Episurf har startet opp igjen etter ferien nå 
3 Likes
meldingspressa går hver dag 
02.09.2021 08:00:00 - Cision International
Episurf : Results from prospective multicentre study with 5-7 years’ follow-up of the first Swedish Episealer® Knee patients accepted for publication
Episurf Medical (Nasdaq: EPIS B) today announces that results from a multicentre study with 5-7 years’ follow-up of Episealer® patients have been accepted for
publication in the scientific journal Archives of Orthopaedic and Trauma Surgery. The publication with the title “Good subjective outcome and low risk of
revision surgery with a novel customized metal implant for focal femoral chondral lesions at a follow-up after a minimum of five years”
3 Likes
Så håper jeg jo at denne spiller ut som et brudd opp nå de nærmeste dagene. og ikke må ned en tur igjen
3 Likes
Mangler volum foreløpig, men det kan jo komme når som helst
På det sjette bruddet, så må det vel skje? 
1 Like
noe sånt, er bare å sitte, volum sammentrekningen over konsolideringen fra oppgangen i mars er ganske tydelig. Eneste jeg kan mislike er at den er volatil. Men har ikke aksjonærlister så vanskelig å vite om noen driver nedsalg